CHENIX (chenodiol) by Leadiant Biosciences is (chenodeoxycholic acid) is a primary bile acid, synthesized from cholesterol in the liver. Approved for cerebrotendinous xanthomatosis (ctx) in adults. First approved in 1983.
Drug data last refreshed 7h ago · AI intelligence enriched 6d ago
CHENIX (chenodiol) is an oral small-molecule bile acid replacement therapy approved in 1983 for cerebrotendinous xanthomatosis (CTX), a rare genetic disorder of bile acid synthesis. It works by replacing deficient chenodeoxycholic acid levels, restoring farnesoid X receptor activation and suppressing accumulation of toxic atypical bile acids and cholestanol. The drug addresses a severe unmet need in a ultra-rare patient population with no alternative treatments.
As a decades-old therapy approaching loss of exclusivity, CHENIX team sizes are likely small and focused on defending market share against newer competitors in an ultra-rare disease space.
(chenodeoxycholic acid) is a primary bile acid, synthesized from cholesterol in the liver. In CTX, the major bile acid synthesis pathways are disrupted due to partial or total deficiency in sterol 27-hydroxylase encoded by the CYP27A1 gene. CTEXLI may act to replace deficient levels of the…
Worked on CHENIX at Leadiant Biosciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
With zero linked job postings and a product in LOE phase, career opportunities on CHENIX are limited and likely concentrated in commercial defense and market access roles. Working on this product would focus on protecting market share in a niche ultra-rare disease segment rather than building a new franchise.